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PL The concept of prediabetes has been much debated. 
One view is that recognition of this condition could 
help to boost efforts to reduce the future burden of 
diabetes and its complications. The counterargument 
is that describing people with an increased risk of type 2 
diabetes as having prediabetes creates more problems 
than benefits in terms of prevention and treatment; 
eg, unnecessary medicalisation and an unsustainable 
burden on health-care systems. 
Prediabetes develops when insulin-producing cells 
in the body are unable to produce enough insulin for 
a given level of insulin resistance. This situation leads 
to prediabetes states such as impaired fasting glucose, 
impaired glucose tolerance, or raised HbA1c, in which 
blood glucose concentrations are higher than normal, 
but lower than those defining diabetes.1 Prediabetes 
increases the risk of diabetes,2 but both prediabetes 
and diabetes might also revert to normoglycaemia, as 
shown in lifestyle and drug-based intervention trials 
and studies of the outcomes of bariatric surgery.1,3,4
In The Lancet Diabetes & Endocrinology, Mohammed Ali 
and colleagues5 report on trends in cardiovascular and 
renal burdens of people with prediabetes in the USA 
from 1988 to 2014, using data from the US National 
Health and Nutrition Examination Surveys (NHANES). 
NHANES is a programme of population-based studies 
designed to assess the health of adults and children in 
the USA. Ali and colleagues did an analysis of NHANES 
data from consecutive, representative cross-sectional 
studies of non-pregnant adults aged 20 years and older 
obtained during 1988–94, 1999–2004, 2005–10, and 
2011–14.5 They estimated, based on the most inclusive 
definition of prediabetes, that the number of Americans 
with prediabetes (ie, fasting plasma glucose [FPG] 
100–125mg/dL or HbA1c 5·7–6·4%) increased from 
56·2 million during 1988–94 to 78·5 million during 
2011–14. When a more stringent definition of prediabetes 
was used (FPG 100–125mg/dL plus HbA1c 5·7–6·4%), 
the corresponding increase was from 12·1 million 
to 19·5 million. In 2011–14, prediabetes status was 
accompanied by multiple risk factors and disorders, 
including hypertension (36·6% [95% CI 32·8–40·5]), 
dyslipidaemia (51·2% [47·0–55·3]), albuminuria (7·7% 
[6·8–8·8]), and reduced estimated glomerular filtration 
rate (4·6% [3·7–5·9]). 
Compared with participants with diagnosed 
diabetes, individuals with prediabetes received less 
treatment. This was particularly true in the case of 
lipid lowering—only about 40% of participants with 
prediabetes and dyslipidaemia were treated, whereas 
more than 70% of patients with diagnosed diabetes 
and dyslipidaemia received lipid-lowering treatment. 
The authors’ conclusion, based on all these findings, is 
that identifying prediabetes might open up valuable 
opportunities to improve the health of the population.
Observational epidemiological studies in the USA, 
such as Framingham research, the Atherosclerotic Risk 
in Communities study, and NHANES, have been very 
useful for the identification of associations between risk 
factors and chronic diseases. Ali and colleagues’ analysis 
provides valuable information about secular trends in 
the key risk factors for diabetes in the USA. However, 
any public health implications should be considered in 
the context of interventional evidence. 
Whether addressing prediabetes would make 
a significant contribution to the prevention of 
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cardiovascular disease is currently unclear. Targeting 
individuals with prediabetes with a 6-year lifestyle 
intervention programme reduced the incidence of 
cardiovascular mortality over 25 years of follow-up in 
the small (n=577) Chinese Da Qing Diabetes Prevention 
trial.6 These findings might not be generalisable to 
European and American populations in view of the 
very different prevention contexts. Although almost 
50% of Chinese adults have hypertension, less than a 
third are being treated, and fewer than one in 12 are in 
control of their blood pressure.7 According to NHANES, 
however, almost 80% of people in the USA with 
hypertension are treated.5 In this context of more 
effective population-level prevention of cardiovascular 
disease, neither additional lifestyle intervention 
nor metformin in prediabetes had an effect on the 
aggregate microvascular outcome in the US Diabetes 
Prevention Program Outcome Study.8  These findings 
were consistent with those reported from the large UK 
ADDITION-Cambridge trial,9 which included more than 
16 000 high-risk participants. In this study, neither 
screening for diabetes plus intensive multifactorial 
treatment for people diagnosed with diabetes, nor 
screening plus routine diabetes care according to 
national guidelines was successful in reducing 10-year 
mortality related to cardiovascular disease or diabetes 
compared with a reference group of patients who were 
not screened for diabetes but were treated in accordance 
with cardiovascular disease-prevention guidelines. 
Some of the findings from Ali and colleagues’ analysis 
imply that any additional cardiovascular benefits from 
specifically targeting individuals with prediabetes 
would be modest.5 In the NHANES study, the 10-year 
risk of cardiovascular disease in 2011–14 according 
to the American Heart Association atherosclerotic 
cardiovascular disease risk calculator showed little 
difference between the people with prediabetes 
(6·9%, 95% CI 6·4–7·4) and those with normal 
glycaemic status (6·3%, 5·9–6·7). This was also the case 
for untreated dyslipidaemia and hypertension. 
Lipid lowering by means of statin therapy is one of 
the cornerstones of cardiovascular-disease prevention 
in people with high or intermediate overall risk.10 
However, it is unknown whether the treatment targets 
for individuals with prediabetes should be as strict as 
for people with diagnosed diabetes, or more relaxed, 
as for the general population. A related uncertainty is 
that statins are associated with a modestly increased 
risk of diabetes,11 a potential harmful effect with 
particular relevance for individuals with prediabetes, for 
whom even a slight increase in glucose concentrations 
might be enough to cross the diagnostic threshold for 
diabetes.11,12 Current opinion is that the benefits of using 
statins to reduce LDL cholesterol concentrations and 
the risk of cardiovascular disease outweigh any harmful 
effects.13 
Although the benefits of addressing prediabetes 
in attempts to prevent cardiovascular disease seem 
modest, this is not the case for diabetes prevention. 
Several trials, including the US Diabetes Prevention 
Program Outcomes Study,8 have shown that intensive 
lifestyle modification can significantly reduce or delay 
the onset of diabetes in people with impaired glucose 
tolerance.1,8 Targeting this group will therefore benefit 
public health. However, the enormous number of 
affected people in the USA and elsewhere might 
overwhelm health-care systems, leading to less-than-
optimal efficiency in terms of preventive efforts. 
The findings reported by Ali and colleagues5 could help 
to resolve this issue in showing a persistent clustering of 
prediabetes with other factors that increase the risk of 
diabetes.1 Further research could build on this clustering 
to develop multifactorial risk-prediction algorithms 
that allow the identification of a more restricted target 
population including only individuals who are at the 
highest risk of developing diabetes within a population 
of people with prediabetes.
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Renal morbidity and mortality in patients with diabetes 
is high, and although angiotensin-receptor blockers have 
been successful in reducing morbidity and mortality, 
the residual risk remains elevated. Patients who do not 
respond to the prescribed drugs contribute substantially 
to this unmet need. This variation in therapy response is 
in part due to heterogeneity in the causes of renal disease 
progression in patients with diabetes.1 To increase the 
therapeutic options available, research has focused on 
pathways beyond the renin–angiotensin system (RAS). 
Several drug targets have been tested by evaluating 
efficacy of drugs to improve surrogate markers such as 
blood pressure, blood glucose concentration, cholesterol, 
HbA1c, and albuminuria. Many promising drugs were 
discovered, which appeared to be particularly effective 
in reducing albuminuria. Unfortunately, only a few have 
reached the stage of trials assessing hard outcomes. This 
high attrition rate is not only due to scarce funding for 
large, expensive, hard outcome trials, but also the fact 
that each new drug must be tested separately through 
to phase 4 trials. To date, at least three promising drugs 
have advanced to the final stage of development: 
atrasentan (SONAR; NCT01858532), canagliflozin 
(CREDENCE; NCT02065791), and finerenone (FIDELIO; 
NCT02540993).
These trials are expected to show that the drug will 
delay the progression of renal disease on top of current 
guideline therapy. The outlook is promising for all three 
drugs; however, no matter how good the outcome, none 
of these drugs will give protection to all patients. This 
expected variation in therapy response is supported by the 
fact that each of these drug classes has shown a variable 
effect on the important surrogate outcome albuminuria 
(figure). If this variability translates into variation in hard 
renal outcomes, it would mean that each trial will have a 
large group of patients who do not benefit from the drug. 
A substantial residual risk is, therefore, likely to remain 
after completion of all three trials.
Far more important than the success of each of these 
three trials individually is that the results will not answer 
the question of what to do with the non-responders 
from each trial. The individual trials will answer whether 
a non-responder to RAS-intervention has benefited from 
the new drug, but not whether a non-responder might 
benefit from one of the other two drugs. Another key 
question that these trials will not answer is whether the 
three drugs induce responses only in the same patients, 
or if each drug provides benefit for a discrete patient 
population. In the best case scenario of three positive 
trials resulting in three new protective mechanisms, we 
could be left with the frustration of having identified 
three discrete groups of non-responders to single agents, 
but being deprived of the means to test their response to 
the other promising alternatives.
The design of studies in this area should be changed 
to overcome this hurdle, and to get answers about how 
to deal with responders and non-responders. Directly 
selecting patients with a positive surrogate marker 
response to a drug into trials of that drug, as well as de-
selecting patients with a negative surrogate marker 
